WallStreetZenWallStreetZen

NASDAQ: VERA
Vera Therapeutics Inc Stock Forecast, Predictions & Price Target

Analyst price target for VERA

Based on 7 analysts offering 12 month price targets for Vera Therapeutics Inc.
Min Forecast
$22.00-42.11%
Avg Forecast
$32.29-15.04%
Max Forecast
$56.00+47.37%

Should I buy or sell VERA stock?

Based on 7 analysts offering ratings for Vera Therapeutics Inc.
Strong Buy
Strong Buy
4 analysts 57.14%
Buy
2 analysts 28.57%
Hold
1 analysts 14.29%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their VERA stock forecasts and price targets.

VERA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-04-05
lockedlocked$00.00+00.00%2024-03-21
lockedlocked$00.00+00.00%2024-01-26
lockedlocked$00.00+00.00%2024-01-25
lockedlocked$00.00+00.00%2023-12-27
JP Morgan
Bottom 14%
14
Strong BuyMaintains$22.00-42.11%2023-11-30
Jefferies
Top 41%
60
Strong BuyUpgrades$26.00-31.58%2023-11-10

1 of 1

Forecast return on equity

Is VERA forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
36%

Forecast return on assets

Is VERA forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

VERA revenue forecast

What is VERA's revenue in the next 3 years based on estimates from 5 analysts?
Avg 1 year Forecast
$20.5M
Avg 2 year Forecast
$115.9M
Avg 3 year Forecast
$328.7M

VERA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
VERA$38.00$32.29-15.04%Strong Buy
NTLA$21.57$64.14+197.37%Buy
RCKT$22.80$54.33+138.30%Strong Buy
KYMR$33.97$40.25+18.49%Buy
KROS$58.28$90.20+54.77%Strong Buy

Vera Therapeutics Stock Forecast FAQ

Is Vera Therapeutics Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 7 Wall Street analysts covering (NASDAQ: VERA) stock is to Strong Buy VERA stock.

Out of 7 analysts, 4 (57.14%) are recommending VERA as a Strong Buy, 2 (28.57%) are recommending VERA as a Buy, 1 (14.29%) are recommending VERA as a Hold, 0 (0%) are recommending VERA as a Sell, and 0 (0%) are recommending VERA as a Strong Sell.

If you're new to stock investing, here's how to buy Vera Therapeutics stock.

What is VERA's revenue growth forecast for 2026-2028?

(NASDAQ: VERA) Vera Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.03%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.06%.

Vera Therapeutics's revenue in 2024 is $0.On average, 5 Wall Street analysts forecast VERA's revenue for 2026 to be $1,114,306,321, with the lowest VERA revenue forecast at $427,448,428, and the highest VERA revenue forecast at $1,783,303,950. On average, 4 Wall Street analysts forecast VERA's revenue for 2027 to be $6,310,717,901, with the lowest VERA revenue forecast at $4,425,860,917, and the highest VERA revenue forecast at $8,816,872,536.

In 2028, VERA is forecast to generate $17,900,396,657 in revenue, with the lowest revenue forecast at $11,702,285,552 and the highest revenue forecast at $25,496,618,059.

What is VERA's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: VERA) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is VERA's Price Target?

According to 7 Wall Street analysts that have issued a 1 year VERA price target, the average VERA price target is $32.29, with the highest VERA stock price forecast at $56.00 and the lowest VERA stock price forecast at $22.00.

On average, Wall Street analysts predict that Vera Therapeutics's share price could fall to $32.29 by Apr 5, 2025. The average Vera Therapeutics stock price prediction forecasts a potential downside of 15.04% from the current VERA share price of $38.00.

What is VERA's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: VERA) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.